Spark Therapeutics’ success with Luxturna is spurring the company to develop more gene therapies for other genetic diseases, Jeffrey D. Marrazzo, the company’s co-founder and CEO, said at the 37th annual J.P. Morgan Healthcare Conference in San Francisco this week.
Luxturna (voretigene neparvovec-rzyl), the first and only gene therapy available in both the United States and Europe, was approved in late 2017 and became available to the public in early 2018.
“Starting with Luxturna, we shipped 75 vials across 2018, representing a strong commercial start for an ultra-orphan
Uncategorized